Company news
Psyence Biomedical Ltd. news in 2025
Psyence Biomedical Ltd.'s news releases, calls and decks from 2025, newest first.
Psyence BioMed Announces Approval for Use of PsyLabs’ Psilocybin Product in Phase IIb Clinical Trial
December 19, 2025
Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical Sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity Science
December 9, 2025
Psyence BioMed Announces Groundbreaking Psilocybin Longevity Research Program
November 25, 2025
Psyence BioMed Reaches Major Breakthrough in Pharmaceutical-Grade Ibogaine Supply for Worldwide Clinical and Therapeutic Markets
November 20, 2025
Psyence BioMed Establishes Ibogaine Operations in Africa Through Strategic Investment in PsyLabs
November 12, 2025
Psyence BioMed Doses Multiple Patients and Expands Clinical Sites in Phase IIb Study for Adjustment Disorder in Palliative Care
November 6, 2025
Psyence BioMed Strengthens Strategic Partnership with PsyLabs Through USD $3,500,000 Follow-On Investment
November 3, 2025
Psyence BioMed to Present at the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025
August 28, 2025
Corporate Update, August 2025
August 4, 2025
Psyence BioMed’s Strategic Collaboration with PsyLabs Yields Breakthrough in High-Purity Ibogaine Production
July 31, 2025
PSYENCE GROUP INC. Announces Update on Previously Announced Non-Brokered Private Placement of Common Shares
June 24, 2025
Psyence BioMed Chief of Global Impact to Speak at Psychedelic Science 2025
June 18, 2025
PSYENCE GROUP INC. Announces Offering of up to C$600,000 Non-Brokered Private Placement of Common Shares
June 17, 2025
Psyence Biomed Regains Full Compliance with NASDAQ Continued Listing Requirements
June 17, 2025
Psyence BioMed Finalizes Agreement with Award-Winning CRO Southern Star Research to Accelerate Phase IIb Clinical Trial
May 27, 2025
Psyence BioMed Announces Effective Date for 1-for-7.97 Reverse Stock Split
May 1, 2025
Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
April 17, 2025
Psyence Group Announces Share Consolidation
April 16, 2025
Psyence BioMed Announces USD$500,000 Follow-On Investment in PsyLabs and Global Ibogaine Supply Agreement
April 15, 2025
Psyence BioMed Signs LOI with Southern Star Research to Expand Phase IIb Clinical Trial in Australia
April 8, 2025
Corporate Update: Psyence Biomedical Ltd Redefines Psychedelic Medicine with a Multi-Asset Strategy, Advancing Clinical Trials and Scalable Manufacturing
March 31, 2025
Psyence Biomed Further Strengthens Scientific Advisory Board with Appointment of Dr. Dan J. Stein
March 18, 2025
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board
March 9, 2025
Psyence Biomed Names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board
February 26, 2025
Decks in 2025
- Investor Presentation (May 2025)
Investor deck · 41 slides · May 15, 2025